Lucy Gentles Bojidar Goranov Elizabeth Matheson Dr Ashleigh Herriott Dr Angelika Kaufmann et al. | Exploring the frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types | 2019 |
|
Dr Ashleigh Herriott Dr Miranda Patterson Professor Nicola Curtin
| Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers | 2017 |
|
Fiona Middleton Dr Miranda Patterson Dr Claire Elstob Dr Sarah Fordham Dr Ashleigh Herriott et al. | Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition | 2015 |
|
Dr Ashleigh Herriott Dr Susan Tudhope Gesa Junge Natalie Rodrigues Dr Miranda Patterson et al. | PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia | 2015 |
|
Dr Jun-yong Huang Dr Ashleigh Herriott
| A deficiency of the Cdk1 phosphorylation of fizzy increases the binding affinity to cyclin B and reduces the affinities to BubR1 and Mad2 in Drosophila melanogaster | 2013 |
|
Dr Ashleigh Herriott Dr Michele Sweeney Emeritus Professor Michael Whitaker Professor Michael Taggart Dr Jun-yong Huang et al. | Kinetochore localized Mad2 and Cdc20 is itself insufficient for triggering the mitotic checkpoint when Mps1 is low in Drosophila melanogaster neuroblasts | 2012 |
|